EP0871476B1 - Dried blood factor composition comprising trehalose - Google Patents
Dried blood factor composition comprising trehalose Download PDFInfo
- Publication number
- EP0871476B1 EP0871476B1 EP96900633A EP96900633A EP0871476B1 EP 0871476 B1 EP0871476 B1 EP 0871476B1 EP 96900633 A EP96900633 A EP 96900633A EP 96900633 A EP96900633 A EP 96900633A EP 0871476 B1 EP0871476 B1 EP 0871476B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- trehalose
- factor viii
- dried
- drying
- nacl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08010169A EP1974741A1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition stabilised by trehalose |
EP10008828A EP2258402A3 (en) | 1995-01-19 | 1996-01-19 | Dried composition |
EP03002147A EP1308170B1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition comprising trehalose |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9501040.1A GB9501040D0 (en) | 1995-01-19 | 1995-01-19 | Dried composition |
GB9501040 | 1995-01-19 | ||
PCT/GB1996/000119 WO1996022107A1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition comprising trehalose |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03002147A Division EP1308170B1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition comprising trehalose |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0871476A1 EP0871476A1 (en) | 1998-10-21 |
EP0871476B1 true EP0871476B1 (en) | 2003-07-23 |
Family
ID=10768253
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96900633A Expired - Lifetime EP0871476B1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition comprising trehalose |
EP03002147A Expired - Lifetime EP1308170B1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition comprising trehalose |
EP08010169A Withdrawn EP1974741A1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition stabilised by trehalose |
EP10008828A Withdrawn EP2258402A3 (en) | 1995-01-19 | 1996-01-19 | Dried composition |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03002147A Expired - Lifetime EP1308170B1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition comprising trehalose |
EP08010169A Withdrawn EP1974741A1 (en) | 1995-01-19 | 1996-01-19 | Dried blood factor composition stabilised by trehalose |
EP10008828A Withdrawn EP2258402A3 (en) | 1995-01-19 | 1996-01-19 | Dried composition |
Country Status (15)
Country | Link |
---|---|
US (2) | US6649386B2 (da) |
EP (4) | EP0871476B1 (da) |
JP (1) | JP3898221B2 (da) |
KR (1) | KR100417593B1 (da) |
CN (1) | CN1152713C (da) |
AT (2) | ATE245442T1 (da) |
AU (1) | AU704317B2 (da) |
CA (2) | CA2210872C (da) |
DE (2) | DE69637749D1 (da) |
DK (2) | DK0871476T3 (da) |
ES (2) | ES2316658T3 (da) |
GB (1) | GB9501040D0 (da) |
PT (2) | PT871476E (da) |
SI (1) | SI1308170T1 (da) |
WO (1) | WO1996022107A1 (da) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10238718B2 (en) | 2014-08-04 | 2019-03-26 | Csl Limited | Factor VIII formulation |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US6964771B1 (en) | 1995-06-07 | 2005-11-15 | Elan Drug Delivery Limited | Method for stably incorporating substances within dry, foamed glass matrices |
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
GB9616536D0 (en) * | 1996-08-06 | 1996-09-25 | Quadrant Holdings Cambridge | Co-amoxiclav dosage form |
AUPO871997A0 (en) * | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
PT2130554E (pt) * | 1999-02-22 | 2012-11-19 | Univ Connecticut | Formulações de factor viii isentas de albumina |
CN100436466C (zh) * | 2001-08-10 | 2008-11-26 | 株式会社林原生物化学研究所 | 海藻糖或麦芽糖醇和金属离子化合物的缔合物 |
US8541002B2 (en) | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
ATE489105T1 (de) * | 2004-03-19 | 2010-12-15 | Baxter Int | Faktor ixa zur behandlung von blutungsstörungen |
WO2005116081A2 (en) | 2004-05-24 | 2005-12-08 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
US8133484B2 (en) | 2006-12-15 | 2012-03-13 | Lifebond Ltd | Hemostatic materials and dressing |
CA2673260A1 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
EP1958618A1 (de) * | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
US20100316625A1 (en) * | 2007-12-21 | 2010-12-16 | Inspiration Biopharmaceuticals, Inc. | Stabilized factor ix formulations containing trehalose |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
NZ586383A (en) * | 2007-12-28 | 2012-11-30 | Baxter Int | Recombinant vwf formulations |
WO2010031007A2 (en) | 2008-09-12 | 2010-03-18 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
EP2601932A1 (en) * | 2008-10-21 | 2013-06-12 | Baxter International Inc. | Lyophilized recombinant VWF formulations |
US20100168018A1 (en) | 2008-11-07 | 2010-07-01 | Baxter International Inc. | Factor viii formulations |
JP5796860B2 (ja) | 2009-12-22 | 2015-10-21 | ライフボンド リミテッドLifebond Ltd | 架橋マトリックスの特性を調節するための酵素的架橋剤の改変 |
JP2014521084A (ja) * | 2011-07-13 | 2014-08-25 | デナトール アクティエボラグ | 液状生体試料の安定化法 |
CN102416171B (zh) * | 2011-12-06 | 2013-12-25 | 中国医学科学院输血研究所 | 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂 |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EA030733B1 (ru) * | 2013-12-19 | 2018-09-28 | Янссен Вэксинс Энд Превеншн Б.В. | Жидкая композиция для сохранения виросом и способ сохранения виросом |
IL293135A (en) | 2015-05-13 | 2022-07-01 | Agenus Inc | A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide |
CN107333750A (zh) * | 2017-06-11 | 2017-11-10 | 成都吱吖科技有限公司 | 一种长时血液细胞稳定剂 |
AU2019261451A1 (en) | 2018-04-26 | 2020-12-03 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
CN114072420A (zh) | 2019-07-04 | 2022-02-18 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
CN116322920A (zh) | 2020-11-09 | 2023-06-23 | 武田药品工业株式会社 | 使用氧化硅吸附从血浆中纯化fviii |
WO2022261716A1 (en) * | 2021-06-16 | 2022-12-22 | Exopharm Limited | Aqueous formulations for preservation of extracellular vesicles |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891319A (en) * | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
WO1994007510A1 (en) * | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
US6171825B1 (en) * | 1997-04-18 | 2001-01-09 | Bayer Corporation | Preparation of recombinant factor VIII in a protein free medium |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361509A (en) | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4495175A (en) * | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
US4806343A (en) * | 1986-03-13 | 1989-02-21 | University Of Southwestern Louisiana | Cryogenic protectant for proteins |
CA1329760C (en) | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
CA2051092C (en) * | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
AU7254894A (en) | 1993-07-23 | 1995-02-20 | Baxter International Inc. | Activated human factor viii and method of preparation |
US5576291A (en) * | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
PT2130554E (pt) | 1999-02-22 | 2012-11-19 | Univ Connecticut | Formulações de factor viii isentas de albumina |
-
1995
- 1995-01-19 GB GBGB9501040.1A patent/GB9501040D0/en active Pending
-
1996
- 1996-01-19 JP JP52213396A patent/JP3898221B2/ja not_active Expired - Fee Related
- 1996-01-19 PT PT96900633T patent/PT871476E/pt unknown
- 1996-01-19 DE DE69637749T patent/DE69637749D1/de not_active Expired - Lifetime
- 1996-01-19 ES ES03002147T patent/ES2316658T3/es not_active Expired - Lifetime
- 1996-01-19 CA CA002210872A patent/CA2210872C/en not_active Expired - Lifetime
- 1996-01-19 CN CNB961926600A patent/CN1152713C/zh not_active Expired - Lifetime
- 1996-01-19 EP EP96900633A patent/EP0871476B1/en not_active Expired - Lifetime
- 1996-01-19 SI SI9630765T patent/SI1308170T1/sl unknown
- 1996-01-19 DK DK96900633T patent/DK0871476T3/da active
- 1996-01-19 US US08/875,796 patent/US6649386B2/en not_active Expired - Lifetime
- 1996-01-19 EP EP03002147A patent/EP1308170B1/en not_active Expired - Lifetime
- 1996-01-19 WO PCT/GB1996/000119 patent/WO1996022107A1/en active IP Right Grant
- 1996-01-19 PT PT03002147T patent/PT1308170E/pt unknown
- 1996-01-19 AT AT96900633T patent/ATE245442T1/de active
- 1996-01-19 EP EP08010169A patent/EP1974741A1/en not_active Withdrawn
- 1996-01-19 CA CA2671383A patent/CA2671383C/en not_active Expired - Lifetime
- 1996-01-19 AT AT03002147T patent/ATE413885T1/de active
- 1996-01-19 DE DE69629209T patent/DE69629209T2/de not_active Expired - Lifetime
- 1996-01-19 KR KR1019970704891A patent/KR100417593B1/ko not_active IP Right Cessation
- 1996-01-19 ES ES96900633T patent/ES2202425T3/es not_active Expired - Lifetime
- 1996-01-19 DK DK03002147T patent/DK1308170T3/da active
- 1996-01-19 EP EP10008828A patent/EP2258402A3/en not_active Withdrawn
- 1996-01-19 AU AU44540/96A patent/AU704317B2/en not_active Expired
-
2009
- 2009-02-13 US US12/371,459 patent/US7803911B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891319A (en) * | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
WO1994007510A1 (en) * | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
US6171825B1 (en) * | 1997-04-18 | 2001-01-09 | Bayer Corporation | Preparation of recombinant factor VIII in a protein free medium |
Non-Patent Citations (11)
Title |
---|
"Physicians Desk Reference, pages onAntihemophilic Factor Recombinant HELIXATE", 1999, GB * |
BLOOD, journal of the American Society of Hematology, 2000, advertisement page; "Questions hemophilia patients are asking" * |
BOEDEKER B.G.D.: "Production processes of licenced recombinant factor VIII preparations", SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 27, no. 4, 2001, pages 385 - 394 * |
BUCKEL P.: "Recombinant Protein Drugs", 2001, BIRKHCUSER VERLAG, CH, pages: 67 - 88 * |
BUNDESVERBAND DE PHARMAZEUTISCHEN INDUSTRIE E.V. (ED.): "Rote Liste 1994", 1994, EDITIO CANTOR, AULENDORF/WÜRTT., DE * |
COLACO C.: "Extraordinary stability of enzymes dried in trehalose: Simplified molecular biology.", BIOTECHNOLOGY, vol. 10, 1992, pages 1007 - 1011 * |
Internet citation: Bayer Biological Products: Research & development: Production of Factor VIII: Patient's Safety. As retrieved on the internet by the Applicant (date not indicated). * |
Internet citation: Hemophilia A concentrates; http://www.med.unc.edu/thromb/comprehe/fviiicon.htm, as retrieved on 28-3-2002 * |
Internet citation; AlphaNine SD / Alphanate / Profilnine SD; http://www.alphather.com/products/ins_alhpa.htm, as retrieved on 19-7-1999 * |
Prescribing information of antihemophilic factor (human) MONOCLATE-P: factor VIII:c pasteurized, monoclonal antibody purified; U.S. license No. 1281; Aventis Behringer L.L.C., Kankakee, IL 60901, USA * |
Rote Liste: Monographs on "Autoplex", "Beriate", Haemoctin", "Immunate STIM plus" and "Octavi". * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10238718B2 (en) | 2014-08-04 | 2019-03-26 | Csl Limited | Factor VIII formulation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0871476B1 (en) | Dried blood factor composition comprising trehalose | |
US7501493B2 (en) | Dried blood factor composition comprising trehalose | |
KR100457485B1 (ko) | 안정한 트란스글루타미나제 제형 및 이의 제조 방법 | |
CZ219497A3 (cs) | Stabilizovaný přípravek s rekombinantním faktorem VIII prostý albuminu s malým obsahem cukru | |
US6887852B1 (en) | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer | |
CN116531323A (zh) | 用于外泌体产品的稳定剂组合物及其应用 | |
KR101710471B1 (ko) | 건조한 트랜스글루타미나제 조성물 | |
US7244824B2 (en) | Dried blood factor composition comprising trehalose | |
CA2301514A1 (en) | Dried biologically or therapeutically active preparations | |
EP1685160A1 (en) | Dry recombinant human alpha 1-antitrypsin formulation | |
JP2003055257A (ja) | 安定な血液凝固第xiii因子製剤 | |
AU738891B2 (en) | Stable transglutaminase preparations and process for producing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970725 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 970725;LV PAYMENT 970725;SI PAYMENT 970725 |
|
17Q | First examination report despatched |
Effective date: 20000229 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: QUADRANT HEALTHCARE (UK) LIMITED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: QUADRANT HEALTHCARE (UK) LIMITED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ELAN DRUG DELIVERY LIMITED |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROSER, BRUCE JOSEPH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REF | Corresponds to: |
Ref document number: 69629209 Country of ref document: DE Date of ref document: 20030828 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ING. HANS LUDESCHER, PATENTABTEILUNG DER SFS GRUPP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030404000 Country of ref document: GR |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20030723 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: QUADRANT DRUG DELIVERY LIMITED Free format text: ELAN DRUG DELIVERY LIMITED#1 MERE WAY, RUDDINGTON#NOTTINGHAM, NG11 6JS (GB) -TRANSFER TO- QUADRANT DRUG DELIVERY LIMITED#1 MERE WAY, RUDDINGTON#NOTTINGHAM, NG11 6JS (GB) |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2202425 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PD4A Free format text: QUADRANT DRUG DELIVERY LIMITED GB Effective date: 20040329 |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: QUADRANT DRUG DELIVERY LIMITED |
|
26N | No opposition filed |
Effective date: 20040426 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20150126 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20150126 Year of fee payment: 20 Ref country code: CH Payment date: 20150126 Year of fee payment: 20 Ref country code: PT Payment date: 20150105 Year of fee payment: 20 Ref country code: IE Payment date: 20150129 Year of fee payment: 20 Ref country code: IT Payment date: 20150126 Year of fee payment: 20 Ref country code: DE Payment date: 20150128 Year of fee payment: 20 Ref country code: LU Payment date: 20150206 Year of fee payment: 20 Ref country code: DK Payment date: 20150126 Year of fee payment: 20 Ref country code: MC Payment date: 20150105 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20150119 Year of fee payment: 20 Ref country code: AT Payment date: 20150102 Year of fee payment: 20 Ref country code: GB Payment date: 20150127 Year of fee payment: 20 Ref country code: GR Payment date: 20150128 Year of fee payment: 20 Ref country code: SE Payment date: 20150128 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20150127 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69629209 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20160118 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Effective date: 20160119 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20160119 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20160118 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 245442 Country of ref document: AT Kind code of ref document: T Effective date: 20160119 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20160426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20160118 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20160119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20160126 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MA Ref document number: 20030404000 Country of ref document: GR Effective date: 20160120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20160120 |